Evoke Pharma Shares Outstanding 2013-2025 | EVOK
Evoke Pharma shares outstanding from 2013 to 2025. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
|
Evoke Pharma Annual Shares Outstanding (Millions of Shares) |
|
|---|---|
| 2024 | 2 |
| 2023 | 0 |
| 2022 | 0 |
| 2021 | 0 |
| 2020 | 0 |
| 2019 | 0 |
| 2018 | 0 |
| 2017 | 0 |
| 2016 | 0 |
| 2015 | 0 |
| 2014 | 0 |
| 2013 | 0 |
| 2012 | 0 |
| 2011 | 0 |
|
Evoke Pharma Quarterly Shares Outstanding (Millions of Shares) |
|
|---|---|
| 2025-09-30 | 3 |
| 2025-06-30 | 3 |
| 2025-03-31 | 3 |
| 2024-12-31 | 2 |
| 2024-09-30 | 1 |
| 2024-06-30 | 1 |
| 2024-03-31 | 1 |
| 2023-12-31 | 0 |
| 2023-09-30 | 0 |
| 2023-06-30 | 0 |
| 2023-03-31 | 0 |
| 2022-12-31 | 0 |
| 2022-09-30 | 0 |
| 2022-06-30 | 0 |
| 2022-03-31 | 0 |
| 2021-12-31 | 0 |
| 2021-09-30 | 0 |
| 2021-06-30 | 0 |
| 2021-03-31 | 0 |
| 2020-12-31 | 0 |
| 2020-09-30 | 0 |
| 2020-06-30 | 0 |
| 2020-03-31 | 0 |
| 2019-12-31 | 0 |
| 2019-09-30 | 0 |
| 2019-06-30 | 0 |
| 2019-03-31 | 0 |
| 2018-12-31 | 0 |
| 2018-09-30 | 0 |
| 2018-06-30 | 0 |
| 2018-03-31 | 0 |
| 2017-12-31 | 0 |
| 2017-09-30 | 0 |
| 2017-06-30 | 0 |
| 2017-03-31 | 0 |
| 2016-12-31 | 0 |
| 2016-09-30 | 0 |
| 2016-06-30 | 0 |
| 2016-03-31 | 0 |
| 2015-12-31 | 0 |
| 2015-09-30 | 0 |
| 2015-06-30 | 0 |
| 2015-03-31 | 0 |
| 2014-12-31 | 0 |
| 2014-09-30 | 0 |
| 2014-06-30 | 0 |
| 2014-03-31 | 0 |
| 2013-12-31 | 0 |
| 2013-09-30 | 0 |
| 2013-06-30 | 0 |
| 2013-03-31 | 0 |
| 2012-09-30 | 0 |
| 2012-06-30 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.019B | $0.010B |
| Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |